일회용 혈액백 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the disposable blood bags market size is expected to grow from USD 480.61 million in 2025 to USD 501.08 million in 2026 and is forecast to reach USD 617.23 million by 2031 at 4.26% CAGR over 2026-2031.

This report is Segmented by Product Type (Single Blood Bag, Double Blood Bag, Triple Blood Bag, Quadruple Blood Bag, Penta Blood Bag), Material (PVC DEHP, PVC DEHP-Free, Non-PVC EVA & Others), End User (Hospitals, Blood Banks, and More), Application (Collection, Transportation/Storage, Processing), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Disposable Blood Bags Market Trends and Insights

Rising surgical procedures & transfusion rates in aging populations

The median age of surgical patients climbed from 56 to 59 years between 2008 and 2020, and forecasts indicate a further increase to 61.5 years by 2030. Elderly individuals often present lower preoperative hematocrit, triggering higher transfusion frequency across orthopedic, cardiovascular, and oncologic specialties. Cardiovascular surgery alone consumed 10-15% of all U.S. blood components in 2024, underscoring a durable demand base. Age-linked comorbidities also elevate complications, prompting hospitals to stock greater inventories of pathogen-reduced platelets and leukoreduced red cells. ISO 13485 and FDA quality mandates compel manufacturers to deliver containers that safeguard product potency for this vulnerable cohort. Collectively, these clinical realities reinforce sustained consumption in the disposable blood bags market.

Increasing prevalence of trauma & chronic diseases requiring blood components

Trauma remains a top cause of mortality among working-age adults, driving acute demand for type-specific packed red cells in emergency rooms across Asia-Pacific urban corridors. Chronic conditions such as sickle-cell disease, thalassemia, and certain cancers now necessitate frequent transfusions, with Asia accounting for more than half of global hematologic disease burden. Expanded insurance coverage and economic growth are improving procedure accessibility, thereby elevating transfusion volumes in mid-tier hospitals. Mobile component therapy programs in LMICs enable remote trauma centers to receive platelets within eight minutes via drone dispatch, compressing the traditional 55-minute ground delivery window. As incidence of non-communicable diseases rises, so does the requirement for consistent, contamination-free bag systems that meet 21 CFR Part 640 standards. These dynamics continually amplify growth in the disposable blood bags market.

Declining birth rates & autologous transfusion techniques in developed markets

Fertility rates in North America and Europe fell below replacement levels, narrowing the obstetric transfusion pool that historically generated stable whole-blood demand. Concurrently, cell-salvage devices reclaim intraoperative blood, allowing orthopedic and cardiac surgeons to return autologous red cells to patients, thus lowering allogeneic usage. Hospitals deploying salvage units recorded 15-30% reductions in donor blood requests during major joint replacements, easing pressure on inventory levels. Although salvage bags still require sterile disposables, volumes are significantly smaller than standard donation sets. Long-term demographic contraction and surgical technology overlap diminish future growth momentum, especially in mature markets of the disposable blood bags industry.

Other drivers and restraints analyzed in the detailed report include:

1. Government initiatives to improve voluntary donation & cold-chain infrastructure
2. Shift toward single-use infection-controlled products
3. Patient Blood Management (PBM) programs reducing transfusion volumes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Single bags retained a 36.42% lead in 2025 as cost-effective whole-blood collection tools for emergent situations and rural drives, anchoring baseline volume in the disposable blood bags market. The disposable blood bags market size for single sets, however, is growing more slowly than multi-chamber configurations as hospitals shift toward component therapy. Quadruple bags, expanding at a 4.34% CAGR, accommodate concurrent preparation of packed red cells, plasma, platelets, and cryoprecipitate, maximizing therapeutic value per donation. Automated Reveos platforms integrate with quadruple kits to standardize yields, delivering 150 plasma ml and >=3X109 platelets per unit, an advantage over manual processes.

Growing recognition of cost-per-therapy metrics strengthens multi-bag appeal among reimbursement-driven hospitals. Double and triple bags maintain relevance in mid-tier facilities that perform moderate platelet demand yet face budgetary constraints. Penta sets, though niche, support advanced pathogen inactivation and add-on filtration, attracting specialized blood centers. Across all variants, ISO 8363 burst-strength criteria and 21 CFR Part 640 sterility mandates govern design, compelling suppliers to refine barrier properties while curbing plasticizer migration. These evolving clinical and compliance parameters ensure sustained product mix evolution within the disposable blood bags market.

The blood transfer bags segment holds the remaining market share and serves as a crucial component in the blood banking and transfusion process. These bags are specifically designed for transporting blood components between collection points and healthcare facilities, ensuring safe and contamination-free transfer of blood products. The segment's growth is supported by the increasing adoption of component separation techniques and the rising need for efficient blood component transportation systems in healthcare settings. The demand is further bolstered by the growing network of blood banks and transfusion centers, particularly in developing regions, along with the increasing emphasis on maintaining proper cold chain management during blood product transportation. This segment is an integral part of the blood transfer bags market within the broader disposable medical bag market.

Complete Report Scope:

• By Product Type (Value, USD million)
  • Single Blood Bag
  • Double Blood Bag
  • Triple Blood Bag
  • Quadruple Blood Bag
  • Penta Blood Bag
• By Material (Value, USD million)
  • PVC DEHP
  • PVC DEHP-free
  • Non-PVC (EVA & others)
• By End User (Value, USD million)
  • Hospitals
  • Blood Banks
  • Diagnostic Centers
  • Others
• By Application (Value)
  • Collection
  • Transportation / Storage
  • Processing (Leukoreduction, etc.)
• By Geography (Value, USD million)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America retained a commanding 38.64% share in 2025, underpinned by robust reimbursement, widespread PBM adoption, and stringent FDA oversight that favors premium, innovative bag systems. California's forthcoming DEHP device ban has already influenced procurement teams to pilot DINCH and EVA alternatives, accelerating material migration timelines across U.S. hospital groups. Canada's national science program funds research on pediatric-safe plasticizers, broadening clinical evidence that informs purchasing decisions nationwide.

Asia-Pacific represents the fastest-growing territory with a projected 4.92% CAGR through 2031 as urbanizing populations drive surgical demand and governments invest in digital blood-management infrastructure. Terumo's USD 15 million localization initiative in Hangzhou illustrates how domestic manufacturing can trim import tariffs and bolster regional supply security. India's mobile donation units now service remote districts, while drone corridors between regional centers and trauma hubs slash delivery lead times by 85%. These capacity expansions feed sustained momentum in the disposable blood bags market.

Europe exhibits measured growth, sustained by replacement of legacy DEHP stocks and harmonization under the SoHO regulation effective August 2027. The United Kingdom's domestic plasma initiative seeks 80% albumin self-reliance, spurring investments in advanced collection kits and cold-chain upgrades. South America and the Middle East-Africa region present untapped opportunity where WHO estimates a 102-million-unit annual shortfall. International collaborations aim to introduce compact, solar-powered refrigeration and simplified multi-bag platforms suited for resource-limited environments. Collectively, regional heterogeneity in regulation, infrastructure, and clinical practice shapes a nuanced, yet steadily expanding disposable blood bags market.

1. Terumo
2. Fresenius
3. Haemonetics
4. MacoPharma
5. Grifols
6. B. Braun
7. JMS Co. Ltd.
8. Shandong Weigao Group Medical Polymer Co. Ltd.
9. Poly Medicure Ltd.
10. HLL Lifecare
11. Demotek Ltd.
12. AdvaCare Pharma
13. Mitra Industries Pvt. Ltd.
14. Neomedic International
15. Span Healthcare Private Ltd.
16. Troge Medical
17. Demophorius Healthcare
18. Eightwe Digital Transformations Pvt. Ltd
19. Mitra Industries Pvt Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising surgical procedures & transfusion rates in aging populations
  • 4.2.2 Increasing prevalence of trauma & chronic diseases requiring blood components
  • 4.2.3 Government initiatives to improve voluntary donation & cold-chain infrastructure
  • 4.2.4 Shift toward single-use infection-controlled products
  • 4.2.5 Emerging adoption of non-PVC eco-friendly bags
  • 4.2.6 Mobile donation units expanding component therapy in LMICs
• 4.3 Market Restraints
  • 4.3.1 Declining birth rates & autologous transfusion techniques in developed markets
  • 4.3.2 Stringent regulatory hurdles for new bag materials
  • 4.3.3 Supply-chain dependence on medical-grade PVC resin price volatility
  • 4.3.4 Patient Blood Management (PBM) programs reducing transfusion volumes
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product Type (Value, USD million)
  • 5.1.1 Single Blood Bag
  • 5.1.2 Double Blood Bag
  • 5.1.3 Triple Blood Bag
  • 5.1.4 Quadruple Blood Bag
  • 5.1.5 Penta Blood Bag
• 5.2 By Material (Value, USD million)
  • 5.2.1 PVC DEHP
  • 5.2.2 PVC DEHP-free
  • 5.2.3 Non-PVC (EVA & others)
• 5.3 By End User (Value, USD million)
  • 5.3.1 Hospitals
  • 5.3.2 Blood Banks
  • 5.3.3 Diagnostic Centers
  • 5.3.4 Others
• 5.4 By Application (Value)
  • 5.4.1 Collection
  • 5.4.2 Transportation / Storage
  • 5.4.3 Processing (Leukoreduction, etc.)
• 5.5 By Geography (Value, USD million)
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Terumo Corporation
  • 6.3.2 Fresenius Kabi AG
  • 6.3.3 Haemonetics Corporation
  • 6.3.4 Macopharma SA
  • 6.3.5 Grifols S.A.
  • 6.3.6 B. Braun Melsungen AG
  • 6.3.7 JMS Co. Ltd.
  • 6.3.8 Shandong Weigao Group Medical Polymer Co. Ltd.
  • 6.3.9 Poly Medicure Ltd.
  • 6.3.10 HLL Lifecare Limited
  • 6.3.11 Demotek Ltd.
  • 6.3.12 \AdvaCare Pharma
  • 6.3.13 Mitra Industries Pvt. Ltd.
  • 6.3.14 Neomedic International
  • 6.3.15 Span Healthcare Private Ltd.
  • 6.3.16 Troge Medical GmbH
  • 6.3.17 Demophorius Healthcare
  • 6.3.18 Eightwe Digital Transformations Pvt. Ltd
  • 6.3.19 Mitra Industries Pvt Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment